Welcome to this week’s edition of 18 Share Tips: our weekly selection of top ASX shares, chosen by leading analysts, that we think are worth considering.
This week Mitch Belichovski of Morgans Financial, Arthur Garipoli of Dolphin Partners Financial Services, and Andrew Wielandt of DP Wealth Advisory share their ‘Buy’, ‘Hold’ and ‘Sell’ recommendations.
Please note these share tips are simply recommendations and are in no way intended as financial advice. These share tips are general advice and don’t take into account any individual’s financial situation. Investors are advised to seek professional financial advice before investing.
Early Access to 18 Share Tips

Every Monday you can tune in for our free share tips release, but The Bull Premium gives you access to before Friday morning, giving you a few extra days to assess, and prepare.
So while you read this Monday’s tips, ask yourself if those extra days could have made all the difference.
Mitch Belichovski, Morgans Financial

BUY RECOMMENDATIONS
BUY – ALS Limited (ALQ)
ALS Limited provides laboratory testing services across key industrial and consumer facing industries, primarily in the commodities and life sciences segments. It operates across 50 countries and 300 locations. ALS is now the dominant global leader in geochemistry testing, which generates high levels of cash amid minimal competition. Excess capital from commodities is used to drive earnings growth in life sciences. Strong industry tailwinds coupled with significant forecast earnings per share growth in full year 2027 suggests ALS is on a continuing growth trajectory.
BUY – Sigma Healthcare (SIG)
Sigma Healthcare is a wholesale distributer of pharmaceutical goods and medicines. Following the merger with Chemist Warehouse to create a leading healthcare franchisor, Sigma recently announced it had signed a memorandum of understanding with Greenlight Healthcare that will launch the Chemist Warehouse brand in the UK market. Sigma will acquire a 75 per cent interest in a number of stores. Chemist Warehouse has averaged opening 33 new stores per annum over the past five years, but this international expansion could expedite growth. SIG is a first class operator that’s likely to continue its impressive growth track record into the future.
HOLD RECOMMENDATIONS
HOLD – Dalrymple Bay Infrastructure (DBI)
The company holds a 99-year lease on the Dalrymple Bay Coal Terminal located in Queensland, an export facility with a capacity of 85 million tonnes a year. The share price has performed well since March as the company retains predictable and resilient cashflows. EBITDA growth is driven by CPI-linked base charges and incremental earnings on commissioned non-expansionary capital expenditure (NECAP) projects. DBI continues to generate long term appeal, delivering an attractive distribution yield. In our view, it also remains a potential merger and acquisition target.
HOLD – ResMed Inc (RMD)
This global company develops, makes, distributes and markets medical devices for diagnosing, treating and managing respiratory conditions, including sleep disordered breathing. RMD management recently flagged emerging cost pressures from Middle East tensions. It was a response to higher fuel prices and early signs of component inflation. However, RMD’s fundamentals remain sound, with consistent execution, strong cash generation and structural growth tailwinds from expanding diagnosis and supplies. In our view, investors should continue holding the stock.
SELL RECOMMENDATIONS
SELL – LGI Limited (LGI)
LGI recovers biogas from landfill and converts it to electricity and environmental products. While LGI provides exposure to the decarbonisation theme, the company competes with several larger entities for landfill gas amid a limited number of larger sites to support electricity generation. The share price pull back between mid April to May 13 is primarily due to ongoing weakness in wholesale electricity prices. Also, according to our analysis, investors are cautious about the Mugga Lane strategic growth project, which potentially poses a risk to EBITDA guidance in fiscal year 2026.
SELL – Technology One (TNE)
TNE is one of Australia’s largest enterprise software-as-a-service companies. TNE provides enterprise resource planning software to thousands of corporations, government departments and statutory authorities. While TNE enjoys strong market positions in Australia and New Zealand, the stock was recently trading on a lofty price-earnings ratio above 65 times, indicating it may be overvalued if growth falters. The company is exposed to higher interest rates and its subsequent implications regarding valuations of technology companies. Some uncertainty exists about the long term impact of artificial intelligence on companies in the broader technology sector.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - market-leading social trading platform - Read our review
Arthur Garipoli, Dolphin Partners Financial Services

BUY RECOMMENDATIONS
BUY – Tuas (TUA)
Tuas operates a mobile telecommunications network in Singapore. It lifted revenue by 26 per cent in the first half of fiscal year 2026 when compared to the prior corresponding period. Underlying EBITDA was up 27 per cent. It generated subscriber growth in mobile and broadband services. Tuas and its subsidiary Simba Telecom have proposed acquiring 100 per cent of M1 to become a major telecommunications provider in Singapore. On May 13, 2026, TUA was awaiting approval for the proposed transaction. If approved, a successful acquisition would leave TUA seeking synergy opportunities amid growing earnings going forward.
BUY – WiseTech Global (WTC)
WiseTech develops and provides software solutions to the global logistics industry. The company recently reaffirmed EBITDA and margin guidance for fiscal year 2026. WTC wasn’t immune to the recent sharp sell off in technology stocks due to potential artificial intelligence disruption. Most broker forecasts are at a significant premium to the recent share price.
HOLD RECOMMENDATIONS
HOLD – Develop Group (DVP)
This company explores and develops mineral resources in Australia, including the Woodlawn zinc- copper project in New South Wales. Other projects include the Sulphur Springs deposit and the Pioneer Dome lithium project in Western Australia. DVP recently announced its flagship Woodlawn zinc-copper project had achieved and exceeded nameplate processing capacity rates of 850,000 tonnes per annum. The achievement of Woodlawn steady state production is a major operational milestone, de-risking the project’s expected cash flows. Also, on May 13, DVP announced it had been awarded a $274 million contract with Core Lithium.
HOLD – NextDC (NXT)
This global data centre operator recently raised capital via a 1 for 5.4 pro rata, non renounceable rights issue to institutions and retail investors at $12.70 a share. Proceeds of more than $1 billion will be used to construct data centres to meet rapidly growing demand from cloud computing customers. A compounded annual growth rate in operating earnings of more than 40 per cent is expected between fiscal years 2025 and 2028, as contracted capacity translates to revenue and earnings going forward.
SELL RECOMMENDATIONS
SELL – Endeavour Group (EDV)
Endeavour operates liquor outlets, hotels and gaming facilities. While Endeavour is a leader in the liquor retailing space, the business is operating in a challenging economic environment involving fierce competition, continuing margin pressure and macroeconomic shocks. Many analysts have cut forecasts to reflect softer trends. Increasing fuel costs in response to the Middle East conflict is imposing pricing pressure throughout its supply chain. Increasing cost of living pressures is another challenge. The shares have fallen from $4.04 on March 2 to trade at $3.23 on May 13. Other stocks appeal more in this economic climate of higher interest rates and cash strapped consumers.
SELL – The a2 Milk Company (A2M)
This infant milk formula company recently initiated a voluntary recall of three small batches of product sold in the United States. The company announced the recall was isolated to the US label product. The shares have remained under pressure since April when the company downgraded guidance in full year 2026. It expects lower infant milk formula sales, mostly related to Chinese labels. The EBITDA percentage margin is forecast to decline from previous guidance of between 15.5 per cent to 16 per cent to between 14 per cent to 14.5 per cent. Other stocks offer more appealing outlooks. The shares have fallen from $9.24 on April 10 to trade at $6.45 on May 13.
Featured Names – The Roundup
| Name | Recommendation | Firm |
|---|---|---|
| ALS Limited (ALQ) | Buy | Morgans Financial |
| Sigma Healthcare (SIG) | Buy | Morgans Financial |
| Tuas (TUA) | Buy | Dolphin Partners Financial Services |
| WiseTech Global (WTC | Buy | Dolphin Partners Financial Services |
| Munro Concentrated Global Growth Active ETF (MCGG) | Buy | DP Wealth Advisory |
| Cleanaway Waste Management (CWY) | Buy | DP Wealth Advisory |
| Dalrymple Bay Infrastructure (DBI) | Hold | Morgans Financial |
| ResMed Inc (RMD) | Hold | Morgans Financial |
| Develop Global (DVP) | Hold | Dolphin Partners Financial Services |
| NextDC (NXT) | Hold | Dolphin Partners Financial Services |
| Vanguard MSCI Index International Shares ETF (VGS) | Hold | DP Wealth Advisory |
| Codan (CDA) | Hold | DP Wealth Advisory |
| LGI Limited (LGI) | Sell | Morgans Financial |
| Technology One (TNE) | Sell | Morgans Financial |
| Endeavour Group (EDV) | Sell | Dolphin Partners Financial Services |
| The a2 Milk Company (A2M | Sell | Dolphin Partners Financial Services |
| James Hardie Industries PLC (JHX) | Sell | DP Wealth Advisory |
| Temple & Webster Group (TPW) | Sell | DP Wealth Advisory |
The above recommendations are general advice and don’t take into account any individual’s objectives, financial situation or needs. Investors are advised to seek their own professional advice before investing. Please note that TheBull.com.au simply publishes broker recommendations on this page. The publication of these recommendations does not in any way constitute a recommendation on the part of TheBull.com.au. You should seek professional advice before making any investment decisions.
